1. In two large randomized platform trials, early treatment with nirmatrelvir–ritonavir did not reduce hospitalization or death among mostly vaccinated, ...
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. In this retrospective cohort study, the virologic rebound (VR) of coronavirus disease 2019 (COVID-19) occurred far more frequently in ...
1. In this retrospective cohort study, nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and mortality associated with coronavirus disease 2019 ...
1. In this trial emulation study, molnupiravir and nirmatrelvir-ritonavir reduced all-cause mortality in vaccinated and unvaccinated hospitalized patients with coronavirus ...
1. VV116 is noninferior compared to nirmatrelvir-ritonavir for achieving sustained recovery in mild-to-moderate coronavirus disease 2019 (COVID-19) cases. 2. Participants ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
